Skip to content

Evaluation of the efficacy of butofino combined with dexmedetomidine compared with traditional sufentanil in the analgesia of patients with invasive mechanical ventilation in ICU

Evaluation of the efficacy of butofino combined with dexmedetomidine compared with traditional sufentanil in the analgesia of patients with invasive mechanical ventilation in ICU

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000038721
Enrollment
Unknown
Registered
2020-09-29
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ICU endotracheal intubation mechanical ventilation

Interventions

Control group:Sufentanil Analgesic Treatment
Experimental group:Butofino combined with dexmedetomidine for analgesia

Sponsors

Affiliated Hospital of Guizhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients who were transferred to the Department of Critical Care Medicine, Affiliated Hospital of Guizhou Medical University, were older than 18 years old and required invasive mechanical ventilation through oral endotracheal intubation.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women; 2. Moderate to severe renal dysfunction (Scr>178umol/l, urea nitrogen>9mmol/l) and moderate to severe liver function (Child-Pugh) Grade C or above) Patients; 3. Patients with pre-existing dementia or obvious stroke sequelae, patients with cerebral hemorrhage, traumatic brain injury and other mentally unable to assess; 4. Allergic to opioids and benzodiazepines; 5. Long-term People who use opioids, benzodiazepines and psychotropic drugs; 6. Bradycardia, atrioventricular block of more than second degree; 7. Serious circulatory instability when transferred to ICU, requiring high-dose boost Drug maintenance; 8. After cardiopulmonary resuscitation.

Design outcomes

Primary

MeasureTime frame
Dosage of analgesics;Dosage of sedative drugs;Ventilator time;Pull out the tracheal intubation time;ICU stay time;

Secondary

MeasureTime frame
Incidence of delirium;Liver and kidney function;Gastrointestinal function;28-day case fatality rate;

Countries

China

Contacts

Public ContactShen Feng
doctorshenfeng@163.com+86 13511999117

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026